Altered Treg and cytokine responses in RSV-infected infants

Pediatric Research

Volumn 80, Issue 5, 2016, Pages 702-709

  Christiaansen, Allison F ^a   Syed, Muhammad A ^b   Ten Eyck, Patrick P ^a   Hartwig, Stacey M ^a   Durairaj, Lakshmi ^b   Kamath, Sameer S ^b   Varga, Steven M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; CYTOKINE; IL17A PROTEIN, HUMAN; IL23A PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 23P19; INTERLEUKIN 33;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFANT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE ACTIVATION; BLOOD; BRONCHIOLITIS; CASE CONTROL STUDY; CYTOLOGY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFLAMMATION; MONONUCLEAR CELL; NEWBORN; NOSE MUCOSA; PNEUMONIA; VIROLOGY;

BRONCHIOLITIS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKIN-33; LEUKOCYTES, MONONUCLEAR; MALE; NASAL MUCOSA; PNEUMONIA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; T-LYMPHOCYTES, REGULATORY;

EID: 84994086608     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2016.130     Document Type: Article

References (41)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet 2010;375:1545-55.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140: 543-6.
3. García CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatr 2010;126:e1453-60.
4. Rivera CA, Gomez RS, Diaz RA, et al. Novel therapies and vaccines against the human respiratory syncytial virus. Expert Opin Investig Drugs 2015;24:1613-30.
5. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
6. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Pediatr 2014 134 415-420.
7. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007;20:108-19.
8. Peebles RS Jr, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2005;2:110-5.
9. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-33.
10. Everard ML, Swarbrick A, Wrightham M, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994;71:428-32.
11. Heidema J, Lukens MV, van Maren WW, et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol 2007;179:8410-7.
12. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001;184:393-9.
13. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003;168:633-9.
14. Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J 2013;32:e437-42.
15. Mangodt TC, Van Herck MA, Nullens S, et al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatr Res 2015;78: 483-91.
16. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 2014;59:109-17.
17. Tekkanat KK, Maassab HF, Cho DS, et al. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol 2001;166:3542-8.
18. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011;179:248-58.
19. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol 2011;187:3145-54.
20. Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 2010;185:2382-92.
21. Loebbermann J, Thornton H, Durant L, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol 2012;5:161-72.
22. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009;83:3019-28.
23. Christiaansen AF, Boggiatto PM, Varga SM. Limitations of Foxp3(+) Treg depletion following viral infection in DEREG mice. J Immunol Methods 2014;406:58-65.
24. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-Associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
25. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21:629-32.
26. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
27. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009;106:9021-6.
28. Faber TE, Groen H, Welfing M, Jansen KJ, Bont LJ. Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis. J Med Virol 2012;84:1084-8.
29. Larrañaga CL, Ampuero SL, Luchsinger VF, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J 2009;28:867-73.
30. Raiden S, Pandolfi J, Payaslián F, et al. Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children. Am J Respir Crit Care Med 2014;189:865-8.
31. Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJ. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol 2013;87:10946-54.
32. Saravia J, You D, Shrestha B, et al. Respiratory syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog 2015;11:e1005217.
33. Liu J, Wu J, Qi F, et al. Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. Int Immunopharmacol 2015;28: 337-43.
34. Zeng S, Wu J, Liu J, Qi F, Liu B. IL-33 Receptor (ST2) signalling is important for regulation of Th2-mediated airway inflammation in a murine model of acute respiratory syncytial virus infection. Scand J Immunol 2015;81:494-501.
35. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel alarmin?. PLoS One 2008;3:e3331.
36. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-Associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007;104:282-7.
37. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011;7:321-9.
38. Tjota MY, Williams JW, Lu T, et al. IL-33-dependent induction of allergic lung inflammation by Fc?RIII signaling. J Clin Invest 2013;123:2287-97.
39. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014; 513:564-8.
40. Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31:84-98.
41. Larrañaga CL, Ampuero SL, Luchsinger VF, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J 2009;28: 867-73.